Other-Net, Expense (Income)

3 Months Ended

Mar. 31, 2013

Nonoperating Income (Expense) [Abstract]

Other - Net, Expense (Income) [Text Block]

Note 14: Other—Net, (Income) Expense

Other–net, (income) expense consisted of the following:

	Three Months Ended
	March 31,
	2013			2012
Income related to transfer of exenatide commercial rights (Note 4)	$	(495.4	)	$	—
Interest expense	40.3			45.3
Interest income	(23.6		)	(26.1		)
Other	(50.5		)	26.8
Other—net, (income) expense	$	(529.2	)	$	46.0

Other—net, income of $529.2 million for the first three months of 2013 is primarily related to the income recognized from the transfer to Amylin of exenatide commercial rights in all markets outside the United States. See Note 4 for additional information.